Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Molecular Therapy

Volumn 25, Issue 10, 2017, Pages 2245-2253

  Kochenderfer, James N ^a   Somerville, Robert P T ^b   Lu, Tangying ^b   Yang, James C ^b   Sherry, Richard M ^b   Feldman, Steven A ^b   McIntyre, Lori ^b   Bot, Adrian ^b   Rossi, John ^b   Lam, Norris ^a   Rosenberg, Steven A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Kite Pharma Inc   (United States)

Author keywords

adoptive T cell therapy; chimeric antigen receptors; lymphoma

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; VIDARABINE;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN DEFICIENCY; MALE; MIDDLE AGED; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; BLOOD; IMMUNOLOGY; PROCEDURES;

ADULT; ANTIGENS, CD19; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VIDARABINE;

EID: 85028330613     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.07.004     Document Type: Article

References (40)

1. Sadelain, M., Brentjens, R., Rivière, I., The basic principles of chimeric antigen receptor design. Cancer Discov. 3 (2013), 388–398.
2. Kochenderfer, J.N., Rosenberg, S.A., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10 (2013), 267–276.
3. Kenderian, S.S., Porter, D.L., Gill, S., Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol. Blood Marrow Transplant. 23 (2017), 235–246.
4. Ramos, C.A., Heslop, H.E., Brenner, M.K., CAR-T cell therapy for lymphoma. Annu. Rev. Med. 67 (2016), 165–183.
5. Sadelain, M., CAR therapy: the CD19 paradigm. J. Clin. Invest. 125 (2015), 3392–3400.
6. Jensen, M.C., Riddell, S.R., Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33 (2015), 9–15.
7. Jackson, H.J., Rafiq, S., Brentjens, R.J., Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13 (2016), 370–383.
8. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
9. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
10. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33 (2015), 540–549.
11. Turtle, C.J., Hanafi, L.A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med., 8, 2016, 355ra116.
12. Locke, F.L., Neelapu, S.S., Bartlett, N.L., Siddiqi, T., Chavez, J.C., Hosing, C.M., Ghobadi, A., Budde, L.E., Bot, A., Rossi, J.M., Jiang, Y., Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25 (2017), 285–295.
13. Kochenderfer, J.N., Somerville, R.P.T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S.L., Yang, J.C., Sherry, R.M., et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35 (2017), 1803–1813.
14. Ramos, C.A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R.T., Gee, A.P., et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J. Clin. Invest. 126 (2016), 2588–2596.
15. Martelli, M., Ferreri, A.J.M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., Pileri, S.A., Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87 (2013), 146–171.
16. Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116 (2010), 2040–2045.
17. Friedberg, J.W., Relapsed/refractory diffuse large B-cell lymphoma. ASH Education Book 2011 (2011), 498–505.
18. Elstrom, R.L., Martin, P., Ostrow, K., Barrientos, J., Chadburn, A., Furman, R., Ruan, J., Shore, T., Schuster, M., Cerchietti, L., et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin. Lymphoma Myeloma Leuk. 10 (2010), 192–196.
19. Nagle, S.J., Woo, K., Schuster, S.J., Nasta, S.D., Stadtmauer, E., Mick, R., Svoboda, J., Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am. J. Hematol. 88 (2013), 890–894.
20. Vose, J.M., Bierman, P.J., Anderson, J.R., Kessinger, A., Pierson, J., Nelson, J., Frappier, B., Schmit-Pokorny, K., Weisenburger, D.D., Armitage, J.O., Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80 (1992), 2142–2148.
21. Brudno, J.N., Somerville, R.P.T., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., Gea-Banacloche, J.C., Pavletic, S.Z., Hickstein, D.D., Lu, T.L., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34 (2016), 1112–1121.
22. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
23. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
24. Brudno, J.N., Kochenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (2016), 3321–3330.
25. Vidal, L., Gafter-Gvili, A., Salles, G., Bousseta, S., Oberman, B., Rubin, C., van Oers, M.H., Fortpied, C., Ghielmini, M., Pettengell, R., et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur. J. Cancer 76 (2017), 216–225.
26. Leone, G., Mele, L., Pulsoni, A., Equitani, F., Pagano, L., The incidence of secondary leukemias. Haematologica 84 (1999), 937–945.
27. Bhatia, S., Therapy-related myelodysplasia and acute myeloid leukemia. Semin. Oncol. 40 (2013), 666–675.
28. Perez-Andres, M., Paiva, B., Nieto, W.G., Caraux, A., Schmitz, A., Almeida, J., Vogt, R.F. Jr., Marti, G.E., Rawstron, A.C., Van Zelm, M.C., et al., Primary Health Care Group of Salamanca for the Study of MBL. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin. Cytom. 78:Suppl 1 (2010), S47–S60.
29. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
30. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008), 5233–5239.
31. Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., Wilson, W.H., Rosenberg, S.A., Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32 (2009), 689–702.
32. Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P., Rosenberg, S.A., Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116 (2010), 3875–3886.
33. Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., Antony, P.A., Palmer, D.C., Spiess, P.J., Hwang, L.N., Yu, Z., Wrzesinski, C., Heimann, D.M., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202 (2005), 907–912.
34. Klebanoff, C.A., Khong, H.T., Antony, P.A., Palmer, D.C., Restifo, N.P., Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26 (2005), 111–117.
35. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., et al., International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25 (2007), 579–586.
36. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 (2009), 535–546.
37. Warren, E.H., Fujii, N., Akatsuka, Y., Chaney, C.N., Mito, J.K., Loeb, K.R., Gooley, T.A., Brown, M.L., Koo, K.K., Rosinski, K.V., et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 115 (2010), 3869–3878.
38. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
39. Kochenderfer, J.N., Dudley, M.E., Carpenter, R.O., Kassim, S.H., Rose, J.J., Telford, W.G., Hakim, F.T., Halverson, D.C., Fowler, D.H., Hardy, N.M., et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122 (2013), 4129–4139.
40. Ali, S.A., Shi, V., Maric, I., Wang, M., Stroncek, D.F., Rose, J.J., Brudno, J.N., Stetler-Stevenson, M., Feldman, S.A., Hansen, B.G., et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 (2016), 1688–1700.